Achilles Therapeutics (NASDAQ:ACHL) ADRs added ~42% in the premarket on Thursday after the U.K.-based biotech announced plans to explore strategic alternatives and close its CHIRON and THETIS clinical...
Source LinkAchilles Therapeutics (NASDAQ:ACHL) ADRs added ~42% in the premarket on Thursday after the U.K.-based biotech announced plans to explore strategic alternatives and close its CHIRON and THETIS clinical...
Source Link
Comments